Atea initiates first-in-human Phase 1 trial of AT-587 for hepatitis E virus

Atea Pharmaceuticals initiated a first-in-human Phase 1 trial of AT-587 for hepatitis E virus, a disease with no approved therapies.

The randomized, double-blind, placebo-controlled study in healthy volunteers is designed to assess safety, tolerability, pharmacokinetics, food effect, single ascending dose (SAD), and multiple ascending dose (MAD).

Preclinical data cited 30- to 150-fold higher in vitro potency versus sofosbuvir and ribavirin, with in vivo activity shown in an HEV genotype 3 model.

The program positions AT-587 as a potential first-in-class oral HEV treatment, targeting immunocompromised patients at risk of chronic infection.